GRI: היקף יתרות המזומנים של החברה GRI Bio

GRI Bio, Inc. (GRI) is diversifying its scientific risks by developing unique immunological treatments for fibrotic pathologies. This free cash flow chart confirms the current liquidity status, where the metric has reached the level of 0.01. The absence of regular sales ties the company's market capitalization to test results. The viability of the model relies on the successful safety validation of the drugs and securing investments to complete early-stage R&D.
פילוחים אנליטיים ודוחות נתונים של חברת GRI Bio Inc (GRI)

This indicator determines the volume of liquid assets that form the foundation of the issuer's solvency. For GRI Bio, Inc. (GRI), this is a critical metric, as the absence of sales and high R&D costs make the company dependent on its capital reserves. The trend in cash holdings clearly demonstrates the burn rate of resources on clinical trials. Analysis of this chart allows for an assessment of the risk of funding shortages when scaling the pipeline. A stable cash balance confirms the financial viability of the business.